JCI Insight (Apr 2022)

Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults

  • Ruth A. Karron,
  • Maria Garcia Quesada,
  • Elizabeth A. Schappell,
  • Stephen D. Schmidt,
  • Maria Deloria Knoll,
  • Marissa K. Hetrich,
  • Vic Veguilla,
  • Nicole Doria-Rose,
  • Fatimah S. Dawood,
  • SEARCh Study Team

Journal volume & issue
Vol. 7, no. 8

Abstract

Read online

Background SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children.Methods We compared receptor binding domain–binding antibody (RBDAb) titers and SARS-CoV-2–neutralizing antibody titers, measured by pseudovirus-neutralizing antibody assay in serum specimens obtained from children aged 0–4 years and 5–17 years and in adults aged 18–62 years at the time of enrollment in a prospective longitudinal household study of SARS-CoV-2 infection.Results Among 56 seropositive participants at enrollment, children aged 0–4 years had more than 10-fold higher RBDAb titers than adults (416 vs. 31, P < 0.0001) and the highest RBDAb titers in 11 of 12 households with seropositive children and adults. Children aged 0–4 years had only 2-fold higher neutralizing antibody than adults, resulting in higher binding-to-neutralizing antibody ratios compared with adults (2.36 vs. 0.35 for ID50, P = 0.0004).Conclusion These findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutralizing antibody to measure the immunogenicity of COVID-19 vaccines in children aged 0–4 years.Funding CDC (award 75D30120C08737).

Keywords